Table 1 Baseline characteristics for patients randomized to double-blind adalimumab (ADA) 40 mg every 2 weeks or tofacitinib 10 mg twice daily (BID) in the phase 3 study [10] and for the subgroup who then received open-label tofacitinib 10 mg BID in the extension study [13]
From: Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Double-blind study | Double-blind to open-label extensiona | |||
|---|---|---|---|---|
ADA 40 mg | Tofacitinib 10 mg | ADA to tofacitinib | Tofacitinib to tofacitinib | |
n = 204 | n = 201 | n = 107 | n = 126 | |
Female, n (%) | 162 (79.4) | 168 (83.6) | 83 (77.6) | 107 (84.9) |
White, n (%) | 148 (72.5) | 143 (71.1) | 90 (84.1) | 98 (77.8) |
Age in years, mean ± SD | 52.5 ± 11.7 | 52.9 ± 11.8 | 52.2 ± 11.4 | 51.6 ± 11.2 |
Region of origin, % | ||||
North America | 25.5 | 24.9 | 16.8 | 20.6 |
South America | 2.9 | 1.5 | 4.7 | 1.6 |
Europe | 53.9 | 55.7 | 60.7 | 59.5 |
Rest of world | 17.6 | 17.9 | 17.8 | 18.3 |
Tender and swollen joints, mean | ||||
Tender | 26.7 | 26.1 | 28.0 | 25.6 |
Swollen | 16.4 | 15.8 | 16.8 | 16.1 |
Mean HAQ-DI score | 1.5 | 1.5 | 1.5 | 1.5 |
Mean DAS28-4(ESR) | 6.4 | 6.5 | 6.4 | 6.4 |
Mean CRP (mg/L) | 17.5 | 17.3 | 16.2 | 17.9 |
Positive for rheumatoid factor, % | 68.2 | 66.2 | 66.4 | 65.9 |
Positive for anti-CCP, % | 74.8 | 64.0 | 74.8 | 65.1 |
Prior therapy, n (%) | ||||
TNF inhibitor | 16 (7.8) | 14 (7.0) | 12 (11.2) | 10 (7.9) |
Non-TNF inhibitor biologic agent | 3 (1.5) | 4 (2.0) | 1 (0.9) | 3 (2.4) |
Disease-modifying drug other than MTX | 114 (55.9) | 115 (57.2) | 66 (61.7) | 80 (63.5) |
Concomitant therapy, n (%) | ||||
Glucocorticoids | 125 (61.3) | 129 (64.2) | 63 (58.9) | 77 (61.1) |
Lipid-lowering medication | 10 (4.9) | 10 (5.0) | 6 (5.6) | 6 (4.8) |